Invitrogen 3rd Quarter Earnings Announcement Set for October 23, 2003; Conference Call and Slide...

Business Editors/Health/Medical Writers

CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 8, 2003

Invitrogen Corp. (Nasdaq: IVGN) today announced details for its upcoming earnings release, conference call and slide Webcast.

Invitrogen will issue a press release containing its

third quarter financial results on Oct. 23, 2003 at 9 a.m. Eastern Time, followed by a conference call at 11 a.m. Eastern. To listen to the live conference call, dial 201-689-8049 after 10:50 a.m. Eastern. A replay of the call will be available until Oct. 30 by dialing 877-660-6853 and using account number 1628, confirmation number 79229.

The slides and audio portion of the call can be heard live over the Internet at http://www.vcall.com/CEPage.asp?ID=84821 and will be archived at this address for 30 days. You will need RealPlayer for the Webcast.

The company has regularly reported pro forma results that exclude merger related amortization and business integration costs to provide a supplemental comparison of results of operations. Management excludes these costs when analyzing operations since they are principally non-cash or other costs resulting primarily from business restructurings or purchase accounting, which are separate from ongoing operations. Management also believes that the pro forma results provide investors with additional useful information concerning the company's ability to generate cash flow. The financial information excluding these items should be considered in addition to, not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. A reconciliation of Invitrogen's pro forma financial results to financial results calculated in accordance with GAAP is presented on Invitrogen's Web site at: http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=ivgn&item_id= 'proforma.html'&script=11905

About Invitrogen

Invitrogen Corp. (Nasdaq: IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bio-informatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen has headquarters in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 3,000 scientists and other professionals. For more information about Invitrogen, visit the company's Web site at www.invitrogen.com.